• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally.
Market Cap | 284.936 Million | Shares Outstanding | 119.22 Million | Avg 30-day Volume | 1.779 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.16 |
Price to Revenue | 0.9512 | Debt to Equity | -2.3457 | EBITDA | -25.191 Million |
Price to Book Value | 0.0 | Operating Margin | -28.939999999999998 | Enterprise Value | 175.454 Million |
Current Ratio | 3.352 | EPS Growth | 0 | Quick Ratio | 3.051 |
1 Yr BETA | 0.8664 | 52-week High/Low | 0.0 / | Profit Margin | -36.0991 |
Operating Cash Flow Growth | -47.9776 | Altman Z-Score | -13.9555 | Free Cash Flow to Firm | -8.259 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
119,551,297 | 2016-09-07 | 0 | |
|
No longer subject to file | 2016-09-07 | 0 | |
LINTON JEFFREY D SR VP, GC & SECRETARY |
|
No longer subject to file | 2016-09-07 | 0 |
|
No longer subject to file | 2016-09-07 | 0 | |
|
No longer subject to file | 2016-09-07 | 0 | |
EISENBERG GLENN A EVP AND TREASURER |
|
0 | 2016-09-07 | 0 |
EBERTS F SAMUEL III CHAIRMAN, PRESIDENT & SEC |
|
0 | 2016-09-07 | 0 |
|
No longer subject to file | 2016-09-07 | 0 | |
|
No longer subject to file | 2016-09-07 | 0 | |
|
0 | 2016-09-07 | 0 | |
|
No longer subject to file | 2016-09-07 | 0 | |
|
0 | 2016-09-07 | 0 | |
BEAVER CAROLYN SVP & CFO |
|
No longer subject to file | 2016-09-07 | 0 |
VAN DEN BOOM DIRK PRESIDENT & CEO |
|
No longer subject to file | 2016-09-07 | 0 |
WEINER ROBIN SVP CORP GOV & REG AFFAIRS |
|
No longer subject to file | 2016-09-07 | 0 |
|
0 | 2016-09-07 | 0 | |
GROSU DANIEL S MD SVP & CMO |
|
No longer subject to file | 2016-09-07 | 0 |
|
No longer subject to file | 2016-09-07 | 0 | |
LOZUK ROBERT SVP, COMMERCIAL OPS |
|
No longer subject to file | 2016-09-07 | 0 |
|
17,325,000 | 2015-12-30 | 0 | |
WELCH WILLIAM J PRESIDENT & CEO |
|
56,060 | 2015-06-10 | 0 |
|
283,794 | 2015-02-10 | 0 | |
|
0 | 2014-06-10 | 0 | |
MONKO ALEXANDER MICHAEL SR. VP, GENETIC ANALYSIS |
|
No longer subject to file | 2014-05-30 | 0 |
MAIER PAUL V CHIEF FINANCIAL OFFICER |
|
73,789 | 2014-02-10 | 0 |
BOWEN R WILLIAM SR. VP AND GENERAL COUNSEL |
|
21,337 | 2014-02-10 | 0 |
BOMBARD ALLAN CHIEF MEDICAL OFFICER |
|
52,728 | 2014-02-10 | 0 |
CANTOR CHARLES R CHIEF SCIENTIFIC OFFICER |
|
165,663 | 2013-06-19 | 0 |
JUDGE ALISA VP, HUMAN RESOURCES |
|
7,765 | 2013-06-19 | 0 |
|
0 | 2013-06-11 | 0 | |
NEUMANN CLARKE VP & GENERAL COUNSEL |
|
21,907 | 2012-02-07 | 0 |
MYRES LARRY VP, OPERATIONS |
|
4,996 | 2011-07-18 | 0 |
ZIMMERMAN JOSEPH VP & GENERAL MANAGER, SCMM |
|
0 | 2010-08-03 | 0 |
KARSTEN SCHMIDT VP, BUSINESS DEVELOPMENT |
|
25,569 | 2010-02-09 | 0 |
|
0 | 2010-01-04 | 0 | |
MARCELL SHAWN M VP, MOLECULAR DIAG, ONCOL |
|
31,243 | 2009-12-23 | 0 |
FILE JUSTIN J PRINCIPAL ACCTG & FNCL OFCR |
|
1,136 | 2009-09-28 | 0 |
RIDGEBACK CAPITAL INVESTMENTS L.P. |
|
No longer subject to file | 2009-04-29 | 0 |
OWINGS STEVE VP OPS, PRENATAL DIAGNOSTICS |
|
0 | 2009-03-24 | 0 |
HAWRAN PAUL W CHIEF FINANCIAL OFFICER |
|
115,888 | 2009-03-13 | 0 |
STYLLI HARRY PRESIDENT AND CEO |
|
142,511 | 2009-03-13 | 0 |
DRAGON ELIZABETH SR VP, RESEARCH & DEVELOPMENT |
|
0 | 2009-02-09 | 0 |
TATMAN DERECK VP, BUSINESS DEVELOPMENT |
|
0 | 2009-02-09 | 0 |
RIORDAN GARY VP, REG AFFAIRS & QUALITY |
|
0 | 2009-01-16 | 0 |
|
5,872,966 | 2008-07-10 | 0 | |
|
No longer subject to file | 2008-06-10 | 0 | |
SIEMENS VENTURE CAPITAL GMBH |
|
No longer subject to file | 2007-12-31 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|